Journal of Epidemiology and Global Health

<Previous Article In Issue
Next Article In Issue>
Volume 10, Issue 2, June 2020, Pages 178 - 183

Efficacy of DAAs in the Treatment of Chronic HCV: Real-World Data from the Private Health-Care Sector of the Kingdom of Saudi Arabia

Authors
Almoutaz Hashim1, Fadia Almahdi2, Emad Aldin Albaba3, Ohoud Barkia4, Reem Alkasam4, Asmaa Almahmoud2, Ahmed Nabil2, Ayman Alsulaimani4, Mahmoud Mosli5, *
1Department of Medicine, The University of Jeddah, Jeddah, Saudi Arabia
2Pharmaceutical Care and Management Unit, Bupa Arabia, Jeddah, Saudi Arabia
3Department of Medicine, Almana General Hospital, Alkhobar, Saudi Arabia
4Clinical Governance, Bupa Arabia, Jeddah, Saudi Arabia
5Department of Medicine, King Abdulaziz University Hospital, Jeddah, Saudi Arabia
*Corresponding author. Email: mmosli@kau.edu.sa
Corresponding Author
Mahmoud Mosli
Received 10 August 2019, Accepted 5 January 2020, Available Online 18 February 2020.
DOI
10.2991/jegh.k.200117.002How to use a DOI?
Keywords
Hepatitis C virus; treatment; anti-viral; agents; direct acting; real world; Saudi Arabia
Abstract

Background and Aim: The hepatitis C virus (HCV) is considered a global health challenge that requires urgent interventions for prevention and control. In this study, we aimed to evaluate the effectiveness of direct-acting antiviral agents (DAAs) for HCV-infected patients in the Kingdom of Saudi Arabia (KSA).

Patients and Methods: In this retrospective cohort study, we ascertained data of patients treated with DAA-based regimens for chronic HCV in the private health-care sector hospitals of KSA between April 2015 and December 2017. Data regarding presence or absence of liver cirrhosis, virus genotype, quantitative HCV RNA test, fibrosis stage, and history of liver disease were included. The primary end point of the study was the overall cure rate, defined as the number of patients achieving sustained viral response (SVR) rate at least 12 weeks following completion of treatment, divided by the total number of patients included in the study.

Results: A total of 262 patients fulfilled the study inclusion criteria. Adult patients were enrolled, of which 114 (44%) were females and 148 (56%) were males. About 105 of the patients (40%) were cirrhotic and 156 were treatment-naïve patients (60%), 84 patients were interferon (INF) experienced, and 22 patients had previously received new DAAs but failed to achieve SVR. The majority of patients received ledipasvir–sofosbuvir±RBV (57%) with SVR rate of approximately 97%.

Conclusions: Our local real-world data indicate an overall HCV cure rate of 97% following treatment with DDA#x2019;s when prescribed in the private sector. This estimate is acquiescence with previously reported global cure rates.

Copyright
© 2020 Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

<Previous Article In Issue
Next Article In Issue>
Journal
Journal of Epidemiology and Global Health
Volume-Issue
10 - 2
Pages
178 - 183
Publication Date
2020/02/18
ISSN (Online)
2210-6014
ISSN (Print)
2210-6006
DOI
10.2991/jegh.k.200117.002How to use a DOI?
Copyright
© 2020 Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

risenwbib
TY  - JOUR
AU  - Almoutaz Hashim
AU  - Fadia Almahdi
AU  - Emad Aldin Albaba
AU  - Ohoud Barkia
AU  - Reem Alkasam
AU  - Asmaa Almahmoud
AU  - Ahmed Nabil
AU  - Ayman Alsulaimani
AU  - Mahmoud Mosli
PY  - 2020
DA  - 2020/02/18
TI  - Efficacy of DAAs in the Treatment of Chronic HCV: Real-World Data from the Private Health-Care Sector of the Kingdom of Saudi Arabia
JO  - Journal of Epidemiology and Global Health
SP  - 178
EP  - 183
VL  - 10
IS  - 2
SN  - 2210-6014
UR  - https://doi.org/10.2991/jegh.k.200117.002
DO  - 10.2991/jegh.k.200117.002
ID  - Hashim2020
ER  -